S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17

Open Orphan (ORPH) Share Forecast, Price & News

GBX 14.25
0.00 (0.00%)
(As of 05/17/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
983,844 shs
Average Volume
1.89 million shs
Market Capitalization
£95.61 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ORPH News and Ratings via Email

Sign-up to receive the latest news and ratings for Open Orphan and its competitors with MarketBeat's FREE daily newsletter.

Open Orphan logo

About Open Orphan

Open Orphan plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to Big Pharma, biotech, government, and public health organizations. The company has a portfolio of eight human challenge study models for conditions, such as RSV, flu, asthma and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers. The Disease in Motion platform has various potential applications across a range of end users, including big technology, wearables, pharma, and biotech companies. Further, the company provides biometry, data management, and statistics to its various European pharmaceutical clients, as well as drug development consultancy and services, including CMC (chemistry, manufacturing, and controls), and PK and medical writing to a range of European clients. The company is headquartered in London, the United Kingdom.


See More Headlines

Industry, Sector and Symbol

Year Founded

Sales & Book Value

Annual Sales
£36.13 million
Cash Flow
GBX 2.18 per share
Book Value
GBX 3.30 per share


Pretax Margin




Free Float
Market Cap
£95.61 million
Not Optionable

Company Calendar

Next Earnings (Estimated)


Overall MarketRank

0.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Open Orphan (LON:ORPH) Frequently Asked Questions

When is Open Orphan's next earnings date?

Open Orphan is scheduled to release its next quarterly earnings announcement on Wednesday, June 15th 2022.
View our earnings forecast for Open Orphan

Who are Open Orphan's key executives?
Open Orphan's management team includes the following people:
  • Mr. Cathal Martin Friel, Exec. Chairman (Age 57)
  • Dr. Yamin Mohammed Khan Ph.D., CEO & Director (Age 52)
  • Mr. Leo Toole, Group CFO & Director (Age 49)
  • John Sheridan, Chief Operating Officer
  • Mr. Andrew Catchpole, Chief Scientific Officer
  • Dr. Maurice N. Treacy Ph.D., Chief Commercial Officer
What is Open Orphan's stock symbol?

Open Orphan trades on the London Stock Exchange (LON) under the ticker symbol "ORPH."

How do I buy shares of Open Orphan?

Shares of ORPH and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Open Orphan's stock price today?

One share of ORPH stock can currently be purchased for approximately GBX 14.25.

How much money does Open Orphan make?

Open Orphan has a market capitalization of £95.61 million and generates £36.13 million in revenue each year.

How many employees does Open Orphan have?

Open Orphan employs 179 workers across the globe.

What is Open Orphan's official website?

The official website for Open Orphan is www.openorphan.com.

How can I contact Open Orphan?

Open Orphan's mailing address is Ole Maaloees Vej 3, Copenhagen N, Koebenhavn 2200. The company can be reached via phone at 353 1 644 0007.

This page was last updated on 5/18/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.